The INPPL1 gene encodes the inositol polyphosphate phosphatase-like 1 protein, also known as SH2-containing inositol 5'-phosphatase 2 (SHIP2). This protein belongs to the inositol polyphosphate 5-phosphatase family, which regulates cellular signaling by hydrolyzing phosphatidylinositol (3.4.5)-trisphosphate (PIP3) to phosphatidylinositol (3.4)-bisphosphate (PI(3.4)P2). SHIP2 plays a critical role in modulating insulin signaling, receptor tyrosine kinase pathways, and other processes linked to cell growth, survival, and metabolic homeostasis. Its activity impacts downstream effectors like AKT/PKB and MAPK, influencing glucose uptake, apoptosis, and cytoskeletal organization.
INPPL1 antibodies are widely used in research to detect SHIP2 expression, localization, and interactions in various tissues and disease models. Dysregulation of SHIP2 has been implicated in insulin resistance, type 2 diabetes, obesity, and cancer, making these antibodies valuable tools for studying metabolic disorders and oncogenesis. They are employed in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to explore SHIP2's role in cellular pathways and its potential as a therapeutic target. Commercially available antibodies are typically validated for specificity against human, mouse, or rat isoforms, aiding cross-species comparative studies. Research using INPPL1 antibodies continues to uncover its complex regulatory mechanisms and pathophysiological relevance.